Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
36 participants
INTERVENTIONAL
2024-10-31
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Beta2-adrenergic Agonism and Muscle Remodelling
NCT03565302
The Effect of High Dose Salbutamol on Muscle Performance
NCT01415596
cAMP Signaling and Muscle Adaptations
NCT02557581
Physiological Response to Salbutamol and Exercise
NCT03902106
Generation of Biological Samples Positive to Salmeterol for Anti-Doping Control
NCT04195867
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Salmeterol
Participants are administered salmeterol from an inhaler device
Salmeterol
Participants are administered 200 µg salmeterol (8 puffs) from a MDI device
Placebo
Participants are administered placebo from an inhaler device
Placebo
Participants are administered placebo (8 puffs) from a MDI device
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Salmeterol
Participants are administered 200 µg salmeterol (8 puffs) from a MDI device
Placebo
Participants are administered placebo (8 puffs) from a MDI device
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Physically active \>5 hours a week
* Maximum oxygen uptake classified as high or very high
Exclusion Criteria
* Regular intake of medication deemed by the responsible study physician to affect the test parameters (hormonal contraception is accepted for women)
* Chronic or acute illness deemed by the responsible study physician to affect the test parameters
* Deviation from the study protocol
* Lean mass index \>21 kg/m²
* Pregnancy
* Smoker
* Blood donation during the past 3 months
18 Years
40 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Copenhagen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Morten Hostrup, PhD
Associate Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
August Krogh Building
Copenhagen, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SALM_acute
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.